Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
The global Anti-VEGF Drugs for Angiogenesis-related Disease market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Drugs for Angiogenesis-related Disease Industry Forecast” looks at past sales and reviews total world Anti-VEGF Drugs for Angiogenesis-related Disease sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Drugs for Angiogenesis-related Disease sales for 2024 through 2030. With Anti-VEGF Drugs for Angiogenesis-related Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Drugs for Angiogenesis-related Disease industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Drugs for Angiogenesis-related Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Drugs for Angiogenesis-related Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Drugs for Angiogenesis-related Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Drugs for Angiogenesis-related Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Drugs for Angiogenesis-related Disease.
United States market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Drugs for Angiogenesis-related Disease players cover Roche, Bayer, Genentech, Novartis and Coherus BioSciences Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Drugs for Angiogenesis-related Disease market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
What is the 10-year outlook for the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
What factors are driving Anti-VEGF Drugs for Angiogenesis-related Disease market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Drugs for Angiogenesis-related Disease market opportunities vary by end market size?
How does Anti-VEGF Drugs for Angiogenesis-related Disease break out type, application?
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
The global Anti-VEGF Drugs for Angiogenesis-related Disease market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Drugs for Angiogenesis-related Disease Industry Forecast” looks at past sales and reviews total world Anti-VEGF Drugs for Angiogenesis-related Disease sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Drugs for Angiogenesis-related Disease sales for 2024 through 2030. With Anti-VEGF Drugs for Angiogenesis-related Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Drugs for Angiogenesis-related Disease industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Drugs for Angiogenesis-related Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Drugs for Angiogenesis-related Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Drugs for Angiogenesis-related Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Drugs for Angiogenesis-related Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Drugs for Angiogenesis-related Disease.
United States market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Drugs for Angiogenesis-related Disease players cover Roche, Bayer, Genentech, Novartis and Coherus BioSciences Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Drugs for Angiogenesis-related Disease market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
- Ranibizumab
- Brolucizumab
- Aflibercept
- Conbercept
- Faricimab
- Others
- Tumor
- Eye Diseases
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Bayer
- Genentech
- Novartis
- Coherus BioSciences Inc.
- Regeneron
- Qilu Pharmaceutical Co.,Ltd.
- Innovent Biologics
- Anke Biotechnology
- Shenzhen Kangzhe Pharmaceutical Co Ltd
- Chengdu Kanghong Pharmaceutical Group
- Rongchang Biology
- Youzhiyou Bio
What is the 10-year outlook for the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
What factors are driving Anti-VEGF Drugs for Angiogenesis-related Disease market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Drugs for Angiogenesis-related Disease market opportunities vary by end market size?
How does Anti-VEGF Drugs for Angiogenesis-related Disease break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Drugs for Angiogenesis-related Disease by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Drugs for Angiogenesis-related Disease by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Type
2.2.1 Ranibizumab
2.2.2 Brolucizumab
2.2.3 Aflibercept
2.2.4 Conbercept
2.2.5 Faricimab
2.2.6 Others
2.3 Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
2.3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Type (2019-2024)
2.4 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Application
2.4.1 Tumor
2.4.2 Eye Diseases
2.4.3 Others
2.5 Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
2.5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Application (2019-2024)
3 GLOBAL ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY COMPANY
3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Breakdown Data by Company
3.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Product Location Distribution
3.4.2 Players Anti-VEGF Drugs for Angiogenesis-related Disease Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.4 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.5 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.6 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country
5.1.1 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
5.3 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region
6.1.1 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
6.3 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease by Country
7.1.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
7.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease by Country
8.1.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
8.3 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
10.3 Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
10.4 Industry Chain Structure of Anti-VEGF Drugs for Angiogenesis-related Disease
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Drugs for Angiogenesis-related Disease Distributors
11.3 Anti-VEGF Drugs for Angiogenesis-related Disease Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size Forecast by Region
12.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Type
12.7 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.2.3 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Genentech
13.3.1 Genentech Company Information
13.3.2 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.3.3 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Genentech Main Business Overview
13.3.5 Genentech Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.4.3 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Coherus BioSciences Inc.
13.5.1 Coherus BioSciences Inc. Company Information
13.5.2 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.5.3 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Coherus BioSciences Inc. Main Business Overview
13.5.5 Coherus BioSciences Inc. Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.6.3 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Qilu Pharmaceutical Co.,Ltd.
13.7.1 Qilu Pharmaceutical Co.,Ltd. Company Information
13.7.2 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Qilu Pharmaceutical Co.,Ltd. Main Business Overview
13.7.5 Qilu Pharmaceutical Co.,Ltd. Latest Developments
13.8 Innovent Biologics
13.8.1 Innovent Biologics Company Information
13.8.2 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.8.3 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Innovent Biologics Main Business Overview
13.8.5 Innovent Biologics Latest Developments
13.9 Anke Biotechnology
13.9.1 Anke Biotechnology Company Information
13.9.2 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.9.3 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Anke Biotechnology Main Business Overview
13.9.5 Anke Biotechnology Latest Developments
13.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
13.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Company Information
13.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business Overview
13.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
13.11 Chengdu Kanghong Pharmaceutical Group
13.11.1 Chengdu Kanghong Pharmaceutical Group Company Information
13.11.2 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Chengdu Kanghong Pharmaceutical Group Main Business Overview
13.11.5 Chengdu Kanghong Pharmaceutical Group Latest Developments
13.12 Rongchang Biology
13.12.1 Rongchang Biology Company Information
13.12.2 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.12.3 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Rongchang Biology Main Business Overview
13.12.5 Rongchang Biology Latest Developments
13.13 Youzhiyou Bio
13.13.1 Youzhiyou Bio Company Information
13.13.2 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.13.3 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Youzhiyou Bio Main Business Overview
13.13.5 Youzhiyou Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Drugs for Angiogenesis-related Disease by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Drugs for Angiogenesis-related Disease by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Type
2.2.1 Ranibizumab
2.2.2 Brolucizumab
2.2.3 Aflibercept
2.2.4 Conbercept
2.2.5 Faricimab
2.2.6 Others
2.3 Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
2.3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Type (2019-2024)
2.4 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Application
2.4.1 Tumor
2.4.2 Eye Diseases
2.4.3 Others
2.5 Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
2.5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Application (2019-2024)
3 GLOBAL ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY COMPANY
3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Breakdown Data by Company
3.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Product Location Distribution
3.4.2 Players Anti-VEGF Drugs for Angiogenesis-related Disease Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.4 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.5 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.6 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country
5.1.1 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
5.3 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region
6.1.1 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
6.3 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease by Country
7.1.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
7.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease by Country
8.1.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
8.3 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
10.3 Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
10.4 Industry Chain Structure of Anti-VEGF Drugs for Angiogenesis-related Disease
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Drugs for Angiogenesis-related Disease Distributors
11.3 Anti-VEGF Drugs for Angiogenesis-related Disease Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size Forecast by Region
12.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Type
12.7 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.2.3 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Genentech
13.3.1 Genentech Company Information
13.3.2 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.3.3 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Genentech Main Business Overview
13.3.5 Genentech Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.4.3 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Coherus BioSciences Inc.
13.5.1 Coherus BioSciences Inc. Company Information
13.5.2 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.5.3 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Coherus BioSciences Inc. Main Business Overview
13.5.5 Coherus BioSciences Inc. Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.6.3 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Qilu Pharmaceutical Co.,Ltd.
13.7.1 Qilu Pharmaceutical Co.,Ltd. Company Information
13.7.2 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Qilu Pharmaceutical Co.,Ltd. Main Business Overview
13.7.5 Qilu Pharmaceutical Co.,Ltd. Latest Developments
13.8 Innovent Biologics
13.8.1 Innovent Biologics Company Information
13.8.2 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.8.3 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Innovent Biologics Main Business Overview
13.8.5 Innovent Biologics Latest Developments
13.9 Anke Biotechnology
13.9.1 Anke Biotechnology Company Information
13.9.2 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.9.3 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Anke Biotechnology Main Business Overview
13.9.5 Anke Biotechnology Latest Developments
13.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
13.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Company Information
13.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business Overview
13.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
13.11 Chengdu Kanghong Pharmaceutical Group
13.11.1 Chengdu Kanghong Pharmaceutical Group Company Information
13.11.2 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Chengdu Kanghong Pharmaceutical Group Main Business Overview
13.11.5 Chengdu Kanghong Pharmaceutical Group Latest Developments
13.12 Rongchang Biology
13.12.1 Rongchang Biology Company Information
13.12.2 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.12.3 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Rongchang Biology Main Business Overview
13.12.5 Rongchang Biology Latest Developments
13.13 Youzhiyou Bio
13.13.1 Youzhiyou Bio Company Information
13.13.2 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.13.3 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Youzhiyou Bio Main Business Overview
13.13.5 Youzhiyou Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Ranibizumab
Table 4. Major Players of Brolucizumab
Table 5. Major Players of Aflibercept
Table 6. Major Players of Conbercept
Table 7. Major Players of Faricimab
Table 8. Major Players of Others
Table 9. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 10. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Table 11. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Type (2019-2024) & ($ million)
Table 12. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2019-2024)
Table 13. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Type (2019-2024) & (US$/Unit)
Table 14. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 15. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Table 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Application (2019-2024)
Table 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application (2019-2024)
Table 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Application (2019-2024) & (US$/Unit)
Table 19. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Company (2019-2024) & (K Units)
Table 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company (2019-2024)
Table 21. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company (2019-2024) ($ Millions)
Table 22. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company (2019-2024)
Table 23. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Company (2019-2024) & (US$/Unit)
Table 24. Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Producing Area Distribution and Sales Area
Table 25. Players Anti-VEGF Drugs for Angiogenesis-related Disease Products Offered
Table 26. Anti-VEGF Drugs for Angiogenesis-related Disease Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Geographic Region (2019-2024) & (K Units)
Table 30. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Geographic Region (2019-2024)
Table 31. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Geographic Region (2019-2024) & ($ millions)
Table 32. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Geographic Region (2019-2024)
Table 33. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country/Region (2019-2024) & (K Units)
Table 34. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country/Region (2019-2024)
Table 35. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country/Region (2019-2024) & ($ millions)
Table 36. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country/Region (2019-2024)
Table 37. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 38. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2024)
Table 39. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & ($ Millions)
Table 40. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2024)
Table 41. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 42. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 43. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2019-2024) & (K Units)
Table 44. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region (2019-2024)
Table 45. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2019-2024) & ($ Millions)
Table 46. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Region (2019-2024)
Table 47. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 48. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 49. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 50. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2024)
Table 51. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & ($ Millions)
Table 52. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2024)
Table 53. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 54. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 55. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 56. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2024)
Table 57. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & ($ Millions)
Table 58. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2024)
Table 59. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 60. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 62. Key Market Challenges & Risks of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 63. Key Industry Trends of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 64. Anti-VEGF Drugs for Angiogenesis-related Disease Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Anti-VEGF Drugs for Angiogenesis-related Disease Distributors List
Table 67. Anti-VEGF Drugs for Angiogenesis-related Disease Customer List
Table 68. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Region (2025-2030) & (K Units)
Table 69. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Region (2025-2030) & (K Units)
Table 73. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Region (2025-2030) & ($ millions)
Table 74. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2025-2030) & (K Units)
Table 75. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2025-2030) & (K Units)
Table 77. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2025-2030) & ($ millions)
Table 78. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Type (2025-2030) & (K Units)
Table 79. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 80. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Application (2025-2030) & (K Units)
Table 81. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 82. Roche Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 83. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 84. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Roche Main Business
Table 86. Roche Latest Developments
Table 87. Bayer Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 88. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 89. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Bayer Main Business
Table 91. Bayer Latest Developments
Table 92. Genentech Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 93. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 94. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Genentech Main Business
Table 96. Genentech Latest Developments
Table 97. Novartis Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 98. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 99. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Novartis Main Business
Table 101. Novartis Latest Developments
Table 102. Coherus BioSciences Inc. Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 103. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 104. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Coherus BioSciences Inc. Main Business
Table 106. Coherus BioSciences Inc. Latest Developments
Table 107. Regeneron Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 108. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 109. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Regeneron Main Business
Table 111. Regeneron Latest Developments
Table 112. Qilu Pharmaceutical Co.,Ltd. Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 113. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 114. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Qilu Pharmaceutical Co.,Ltd. Main Business
Table 116. Qilu Pharmaceutical Co.,Ltd. Latest Developments
Table 117. Innovent Biologics Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 118. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 119. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Innovent Biologics Main Business
Table 121. Innovent Biologics Latest Developments
Table 122. Anke Biotechnology Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 123. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 124. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Anke Biotechnology Main Business
Table 126. Anke Biotechnology Latest Developments
Table 127. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 128. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 129. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business
Table 131. Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
Table 132. Chengdu Kanghong Pharmaceutical Group Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 133. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 134. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 135. Chengdu Kanghong Pharmaceutical Group Main Business
Table 136. Chengdu Kanghong Pharmaceutical Group Latest Developments
Table 137. Rongchang Biology Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 138. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 139. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 140. Rongchang Biology Main Business
Table 141. Rongchang Biology Latest Developments
Table 142. Youzhiyou Bio Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 143. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 144. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 145. Youzhiyou Bio Main Business
Table 146. Youzhiyou Bio Latest Developments
Table 1. Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Ranibizumab
Table 4. Major Players of Brolucizumab
Table 5. Major Players of Aflibercept
Table 6. Major Players of Conbercept
Table 7. Major Players of Faricimab
Table 8. Major Players of Others
Table 9. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 10. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Table 11. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Type (2019-2024) & ($ million)
Table 12. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2019-2024)
Table 13. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Type (2019-2024) & (US$/Unit)
Table 14. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 15. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Table 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Application (2019-2024)
Table 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application (2019-2024)
Table 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Application (2019-2024) & (US$/Unit)
Table 19. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Company (2019-2024) & (K Units)
Table 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company (2019-2024)
Table 21. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company (2019-2024) ($ Millions)
Table 22. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company (2019-2024)
Table 23. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Company (2019-2024) & (US$/Unit)
Table 24. Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Producing Area Distribution and Sales Area
Table 25. Players Anti-VEGF Drugs for Angiogenesis-related Disease Products Offered
Table 26. Anti-VEGF Drugs for Angiogenesis-related Disease Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Geographic Region (2019-2024) & (K Units)
Table 30. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Geographic Region (2019-2024)
Table 31. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Geographic Region (2019-2024) & ($ millions)
Table 32. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Geographic Region (2019-2024)
Table 33. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country/Region (2019-2024) & (K Units)
Table 34. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country/Region (2019-2024)
Table 35. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country/Region (2019-2024) & ($ millions)
Table 36. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country/Region (2019-2024)
Table 37. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 38. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2024)
Table 39. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & ($ Millions)
Table 40. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2024)
Table 41. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 42. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 43. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2019-2024) & (K Units)
Table 44. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region (2019-2024)
Table 45. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2019-2024) & ($ Millions)
Table 46. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Region (2019-2024)
Table 47. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 48. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 49. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 50. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2024)
Table 51. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & ($ Millions)
Table 52. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2024)
Table 53. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 54. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 55. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2019-2024) & (K Units)
Table 56. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2019-2024)
Table 57. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2019-2024) & ($ Millions)
Table 58. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2019-2024)
Table 59. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2019-2024) & (K Units)
Table 60. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2019-2024) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 62. Key Market Challenges & Risks of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 63. Key Industry Trends of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 64. Anti-VEGF Drugs for Angiogenesis-related Disease Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Anti-VEGF Drugs for Angiogenesis-related Disease Distributors List
Table 67. Anti-VEGF Drugs for Angiogenesis-related Disease Customer List
Table 68. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Region (2025-2030) & (K Units)
Table 69. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Region (2025-2030) & (K Units)
Table 73. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Region (2025-2030) & ($ millions)
Table 74. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2025-2030) & (K Units)
Table 75. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2025-2030) & (K Units)
Table 77. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2025-2030) & ($ millions)
Table 78. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Type (2025-2030) & (K Units)
Table 79. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 80. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Application (2025-2030) & (K Units)
Table 81. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 82. Roche Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 83. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 84. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Roche Main Business
Table 86. Roche Latest Developments
Table 87. Bayer Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 88. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 89. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Bayer Main Business
Table 91. Bayer Latest Developments
Table 92. Genentech Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 93. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 94. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Genentech Main Business
Table 96. Genentech Latest Developments
Table 97. Novartis Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 98. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 99. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Novartis Main Business
Table 101. Novartis Latest Developments
Table 102. Coherus BioSciences Inc. Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 103. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 104. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Coherus BioSciences Inc. Main Business
Table 106. Coherus BioSciences Inc. Latest Developments
Table 107. Regeneron Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 108. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 109. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Regeneron Main Business
Table 111. Regeneron Latest Developments
Table 112. Qilu Pharmaceutical Co.,Ltd. Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 113. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 114. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Qilu Pharmaceutical Co.,Ltd. Main Business
Table 116. Qilu Pharmaceutical Co.,Ltd. Latest Developments
Table 117. Innovent Biologics Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 118. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 119. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Innovent Biologics Main Business
Table 121. Innovent Biologics Latest Developments
Table 122. Anke Biotechnology Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 123. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 124. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Anke Biotechnology Main Business
Table 126. Anke Biotechnology Latest Developments
Table 127. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 128. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 129. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business
Table 131. Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
Table 132. Chengdu Kanghong Pharmaceutical Group Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 133. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 134. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 135. Chengdu Kanghong Pharmaceutical Group Main Business
Table 136. Chengdu Kanghong Pharmaceutical Group Latest Developments
Table 137. Rongchang Biology Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 138. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 139. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 140. Rongchang Biology Main Business
Table 141. Rongchang Biology Latest Developments
Table 142. Youzhiyou Bio Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 143. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 144. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 145. Youzhiyou Bio Main Business
Table 146. Youzhiyou Bio Latest Developments
LIST OF FIGURES
Figure 1. Picture of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 2. Anti-VEGF Drugs for Angiogenesis-related Disease Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Ranibizumab
Figure 10. Product Picture of Brolucizumab
Figure 11. Product Picture of Aflibercept
Figure 12. Product Picture of Conbercept
Figure 13. Product Picture of Faricimab
Figure 14. Product Picture of Others
Figure 15. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type in 2023
Figure 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2019-2024)
Figure 17. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Tumor
Figure 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Tumor (2019-2024) & (K Units)
Figure 19. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Eye Diseases
Figure 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Eye Diseases (2019-2024) & (K Units)
Figure 21. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Others
Figure 22. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Others (2019-2024) & (K Units)
Figure 23. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2023)
Figure 24. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application in 2023
Figure 25. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market by Company in 2023 (K Units)
Figure 26. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company in 2023
Figure 27. Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market by Company in 2023 ($ Million)
Figure 28. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company in 2023
Figure 29. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Geographic Region in 2023
Figure 31. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2019-2024 (K Units)
Figure 32. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2019-2024 ($ Millions)
Figure 33. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2019-2024 (K Units)
Figure 34. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2019-2024 ($ Millions)
Figure 35. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2019-2024 (K Units)
Figure 36. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2019-2024 ($ Millions)
Figure 37. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2019-2024 (K Units)
Figure 38. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2019-2024 ($ Millions)
Figure 39. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2023
Figure 40. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country in 2023
Figure 41. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Figure 42. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Figure 43. United States Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 44. Canada Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 45. Mexico Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 46. Brazil Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 47. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region in 2023
Figure 48. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Regions in 2023
Figure 49. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Figure 50. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Figure 51. China Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 52. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 53. South Korea Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 54. Southeast Asia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 55. India Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 56. Australia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 57. China Taiwan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 58. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2023
Figure 59. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country in 2023
Figure 60. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Figure 61. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Figure 62. Germany Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 63. France Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 64. UK Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 65. Italy Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 66. Russia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 67. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2023
Figure 68. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country in 2023
Figure 69. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Figure 70. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Figure 71. Egypt Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 72. South Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 73. Israel Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 74. Turkey Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 75. GCC Country Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 76. Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease in 2023
Figure 77. Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 78. Industry Chain Structure of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 79. Channels of Distribution
Figure 80. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Forecast by Region (2025-2030)
Figure 81. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Region (2025-2030)
Figure 82. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Forecast by Type (2025-2030)
Figure 83. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Type (2025-2030)
Figure 84. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Forecast by Application (2025-2030)
Figure 85. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 2. Anti-VEGF Drugs for Angiogenesis-related Disease Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Ranibizumab
Figure 10. Product Picture of Brolucizumab
Figure 11. Product Picture of Aflibercept
Figure 12. Product Picture of Conbercept
Figure 13. Product Picture of Faricimab
Figure 14. Product Picture of Others
Figure 15. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type in 2023
Figure 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2019-2024)
Figure 17. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Tumor
Figure 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Tumor (2019-2024) & (K Units)
Figure 19. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Eye Diseases
Figure 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Eye Diseases (2019-2024) & (K Units)
Figure 21. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Others
Figure 22. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Others (2019-2024) & (K Units)
Figure 23. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2023)
Figure 24. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application in 2023
Figure 25. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market by Company in 2023 (K Units)
Figure 26. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company in 2023
Figure 27. Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market by Company in 2023 ($ Million)
Figure 28. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company in 2023
Figure 29. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Geographic Region in 2023
Figure 31. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2019-2024 (K Units)
Figure 32. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2019-2024 ($ Millions)
Figure 33. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2019-2024 (K Units)
Figure 34. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2019-2024 ($ Millions)
Figure 35. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2019-2024 (K Units)
Figure 36. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2019-2024 ($ Millions)
Figure 37. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2019-2024 (K Units)
Figure 38. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2019-2024 ($ Millions)
Figure 39. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2023
Figure 40. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country in 2023
Figure 41. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Figure 42. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Figure 43. United States Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 44. Canada Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 45. Mexico Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 46. Brazil Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 47. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region in 2023
Figure 48. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Regions in 2023
Figure 49. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Figure 50. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Figure 51. China Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 52. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 53. South Korea Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 54. Southeast Asia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 55. India Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 56. Australia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 57. China Taiwan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 58. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2023
Figure 59. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country in 2023
Figure 60. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Figure 61. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Figure 62. Germany Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 63. France Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 64. UK Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 65. Italy Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 66. Russia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 67. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2023
Figure 68. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country in 2023
Figure 69. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2019-2024)
Figure 70. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2019-2024)
Figure 71. Egypt Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 72. South Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 73. Israel Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 74. Turkey Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 75. GCC Country Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2019-2024 ($ Millions)
Figure 76. Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease in 2023
Figure 77. Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 78. Industry Chain Structure of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 79. Channels of Distribution
Figure 80. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Forecast by Region (2025-2030)
Figure 81. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Region (2025-2030)
Figure 82. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Forecast by Type (2025-2030)
Figure 83. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Type (2025-2030)
Figure 84. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Forecast by Application (2025-2030)
Figure 85. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Application (2025-2030)
